Doctor discussion guide:
|
|
|
- Collin Thornton
- 5 years ago
- Views:
Transcription
1 Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects. I have high cholesterol, or I don t know my cholesterol levels which one best describes you? I have been diagnosed with high cholesterol. I don t know my cholesterol levels. Setting treatment goals and tracking your progress Setting goals will help you evaluate the success of your treatment. Ask your doctor to fill out the following chart at your visit. Test My targets My Results LDL-C apob total cholesterol to HDL cholesterol ratio (TC:HDL-C ratio) hs-crp non-hdl cholesterol triglycerides decrease at least 50% less than 2 mmol/l less than 0.80 g/l less than 4.0 less than 2.0 mg/l less than 3.5 mmol/l less than 1.7 mmol/l apob:apoai ratio less than 0.80 Doctor discussion guide: Managing Cholesterol bodyandhealth.canada.com MediResource Inc. 1 of 5
2 Tracking my progress: The table above has a space for today s results. Use the Cholesterol Diary (you can find the diary under Health tools ) to track your progress over time. My treatments (check all that apply; if needed, ask your doctor for help) Medication Statins Crestor (rosuvastatin) Lescol/Lescol XL (fluvastatin) Lipitor (atorvastatin; also in combination with amlodipine under the brand name Caduet ) Mevacor (lovastatin); generic brands also Pravachol (pravastatin; also in combination with acetylsalicylic acid [ASA] under the brand name PravASA ); generic brands also Zocor (simvastatin); generic brands also Cholesterol absorption inhibitor Ezetrol (ezetimibe) Resins Colestid (colestipol) cholestyramine (generic brands) Fibrates Bezalip SR (bezafibrate); generic brands also Lipidil Micro, Lipidil Supra, Lipidil EZ (fenofibrate); generic brands also Lopid (gemfibrozil); generic brands also Niacin (single and combination products) Advicor (niacin plus lovastatin) I m using it I d like to learn more Niaspan, Niaspan FCT (extended-release niacin) Other niacin products (e.g., generic brands of slow-release and immediate-release niacin) I m not currently taking medications for my cholesterol. Doctor discussion guide: Managing Cholesterol bodyandhealth.canada.com MediResource Inc. 2 of 5
3 Other strategies to manage heart disease risk Healthy diet Exercise Reaching/maintaining a healthy weight Regular cholesterol testing I m using it I d like to learn more Managing my side effects My plan to manage side effects (ask your doctor to check all that apply to you and to fill in the blanks): Make sure I m on the most appropriate dose for my medication. (Higher doses tend to have more side effects). Make sure I m taking my medication as directed and not accidentally taking extra doses. Know which side effects to watch for: Contact my doctor if I notice any side effects or changes that worry me. Other: Other concerns about my cholesterol treatment (check all that apply to you) I m not sure if I m on the most appropriate cholesterol medication. I m not sure what my treatment goals are. I don t know if I am reaching my cholesterol targets. I m not sure if I really need my cholesterol medication. I m having trouble staying motivated to take my medication. I m not sure how to use my cholesterol medication. I m concerned that my cholesterol medication may interact with my other medications. I keep forgetting to take my cholesterol medication. Doctor discussion guide: Managing Cholesterol bodyandhealth.canada.com MediResource Inc. 3 of 5
4 I have some questions about my cholesterol treatment 1. Why is it important to lower my cholesterol? 2. How often should I have my cholesterol tested? 3. What do my cholesterol numbers mean? 4. Which numbers are important, and why? 5. What are my treatment goals? 6. Have my cholesterol levels improved? How close am I to reaching my treatment goals? 7. Am I on the most appropriate cholesterol medication? 8. Do I need to make any adjustments to my medication treatment to meet my treatment goals? 9. What else can I do to reach my cholesterol targets and reduce my risk of developing heart disease? For example, what lifestyle changes can I make (such as eating well, physical activity, weight control, quitting smoking, or drinking less)? Why are these lifestyle changes so important in managing cholesterol? 10. Should I have any other tests (such as hs-crp testing) to assess my risk of developing heart disease and its complications? If a new treatment is recommended, I have some questions: 1. How do I use this treatment? 2. What are the benefits of this treatment? How much will this treatment help reduce my cholesterol and my risk of developing heart disease? 3. When can I expect it to start working? 4. What can I do if I m not sure whether my treatment is working? 5. What side effects should I expect? What should I do to reduce my risk, and what should I do if side effects occur? Other questions: Doctor discussion guide: Managing Cholesterol bodyandhealth.canada.com MediResource Inc. 4 of 5
5 Notes: Doctor discussion guide: Managing Cholesterol bodyandhealth.canada.com MediResource Inc. 5 of 5
Doctor discussion guide:
Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.
Cholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
Diseases & Conditions
http://my.clevelandclinic.org Diseases & Conditions About Cholesterol-Lowering Drugs Some people have a genetic predisposition to high blood cholesterol levels. These people may need drug therapy in addition
CHOLESTEROL REDUCING MEDICATIONS. Five Main Categories. 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor
Page 1 of 5 PHA-GEN-002-2004 CHOLESTEROL REDUCING MEDICATIONS Five Main Categories 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor Statins Also called HMG-CoA reductase inhibitors
PATIENT INFORMATION. Medicine To Treat: C ardiac Diseases. Lipid-Lowering Medicines. Statins Fibrates Fat Binding Agents Nicotinic Acid Group
PATIENT INFORMATION Medicine To Treat: C ardiac Diseases Lipid-Lowering Medicines Statins Fibrates Fat Binding Agents Nicotinic Acid Group ABOUT YOUR MEDICINE Your doctor has just prescribed for you: Medicine
Is patient?: Adult of any age with CVD risk factors; Female >50 or post-menopausal; Diagnosed CAD, PVD, TIA/ Stroke, Diabetes, CKD
THE CHAMPLAIN PRIMARY CARE Source: J. Genest, R. McPherson, J. Frohlich, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of
Dyslipidemia Management - Summary. Adults at any age with the following risk factors should be screened for lipids at any age:
Dyslipidemia Management - Summary How do I assess Dyslipidemia? Screening of plasma lipids is recommended in adult men 40 and women that are 50 years of age or who are postmenopausal. Adults at any age
High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
A guide to cholesterol and heart disease for people with diabetes
A guide to cholesterol and heart disease for people with diabetes Assisted by Developed and Sponsored by Pfizer The charity for people with diabetes Assisted by Pfizer Limited 2005. All rights reserved.
Copy right protected Page 1
CHOLESTEROL and TGs LOWERING DRUGS Introduction: Fat (lipids) are combinations (esters) of fatty acids plus an alcohol. The two main fats in the body are triglycerides (TGs) and cholesterol Triglycerides
Dyslipidemia Management. Cardiovascular disease (CVD) causes one third of deaths in Canada. (1) Due to an increase in diabetes, obesity
Dyslipidemia Management Cardiovascular disease (CVD) causes one third of deaths in Canada. (1) Due to an increase in diabetes, obesity and sedentary lifestyle, the prevalence in of CVD Canada is expected
STATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
Simvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
Your cholesterol levels. Questions or concerns
Because you have high cholesterol you should: Know your cholesterol levels Take the medicine to lower cholesterol that your doctor has told you to take Follow your doctor s treatment plan Keep your appointments
How would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
ATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
Primary Care for Patients with HIV/AIDS What makes it different?
HIV and AIDS Management for the Primary Care Provider Carl B. LeBuhn, MD October 4 th, 009 Primary Care for Patients with HIV/AIDS What makes it different? Drug-drug interactions relatively more prevalent
University of Georgia Family & Consumer Sciences. Volume 27 Number 2 Spring 2013
University of Georgia Family & Consumer Sciences Volume 27 Number 2 Spring 2013 Inside this issue: Back to the Basics: Monitoring Blood Glucose Lipid Control in Diabetes Glaucoma and Diabetes Spicy Spanish
Diabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
Achieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
IMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr CADUET (amlodipine besylate and atorvastatin calcium tablets) This leaflet is Part III of a three-part "Product Monograph" published when CADUET was approved for sale
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
Common Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report July 2015 Drug lomitapide (Juxtapid) (oral capsules) Indication As an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis,
Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
Antihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
Information in these slides is used with permission from St. Mary s Cardiac Rehab
Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure
> 130 > 130 (10-20% risk) <130 >160 (<10% risk) 0-1 Risk Factors <160 >160 >190
Pharmacotherapy of Dyslipidemia Disease State Definition Epidemiology Pathophysiology Clinical Presentation Polygenic LDL above 160 or TG HDL below 40-65 million quality for lifestyle changes - 36 million
Hyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ. fenofibrate, NanoCrystal formulation tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION LIPIDIL EZ fenofibrate, NanoCrystal formulation tablets Read this carefully before you start taking LIPIDIL EZ and each
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
1. Diagnosis Table of Contents 1. Diagnosis a. Definition...5 b. Risk Factors...5 c. Screening...6 d. Signs and Symptoms...6 e. Testing and Evaluation
We would like to acknowledge the contribution of the following groups: Vascular Protection Interdisciplinary Working Groups Chronic Disease Physician Advisory Group Chronic Disease Clinical Leadership
Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy.
LIPID CASE 251 Treating HDL Size Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy. I was asked about a 44 year old physically
CRESTOR rosuvastatin calcium tablets
PART III CONSUMER INFORMATION CRESTOR rosuvastatin calcium tablets This leaflet is part of a "Product Monograph" published when CRESTOR was approved for sale in Canada and is designed specifically for
MOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
Full prescribing information is available to doctors and pharmacists on request.
INFORMATION FOR THE CONSUMER Full prescribing information is available to doctors and pharmacists on request. Sandoz Fenofibrate E reduces levels of low density cholesterol (LDL-C or bad cholesterol),
PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
Dyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
Hyperlipidemia. Cardiovascular Disease. Is the leading cause of
Hyperlipidemia Eric M. Pash, R.Ph. Consultant Pharmacist Diamond Drugs, Inc Annual Educational Conference Thursday, April 16, 2015 1 Diamond Pharmacy Services Cardiovascular Disease Is the leading cause
Antihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
Pravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
What do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
IMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ROSUVASTATIN-5 ROSUVASTATIN-10 ROSUVASTATIN-20 ROSUVASTATIN-40 Rosuvastatin Calcium Tablets This leaflet is part of a oduct Monograph published when ROSUVASTATIN was approved
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
Pharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
IMPORTANT: PLEASE READ What GD-amlodipine/atorvastatin does: PART III: CONSUMER INFORMATION Pr GD-amlodipine/atorvastatin
PART III: CONSUMER INFORMATION Pr GD-amlodipine/atorvastatin (amlodipine besylate and atorvastatin calcium tablets) This leaflet is Part III of a three-part "Product Monograph" published when GDamlodipine/atorvastatin
Update on the Treatment of Hyperlipidemia
Update on the Treatment of Hyperlipidemia Wafaa Abou-Zeineddine, PharmD Medstar Washington Hospital Center Washington Metropolitan Society of Health Systems Pharmacists May 30, 2015 Please MUTE phones
SOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
A Review: Atherosclerosis & its treatment
73 Review Article A Review: Atherosclerosis & its treatment Yogesh K. Patil* Department of Pharmacology, Shree Mahavir Institute of Pharmacy, Nashik, Maharashtra, India *yogesh_kpatil85@yahoo.co.in ABSTRACT
Atorvastatin and upper arm pain
P ford residence southampton, ny Atorvastatin and upper arm pain Caduet (amlodipine and atorvastatin ) is used to treat high blood pressure or angina in patients with high cholesterol. Includes Caduet
Novel Therapeutic Strategies in Lipid Management: Lowering LDL C to Improve Patient Outcomes
Novel Therapeutic Strategies in Lipid Management: Lowering LDL C to Improve Patient Outcomes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology University of Pennsylvania April 25,
Achieve Your Best Health
Achieve Your Best Health for High Cholesterol paisc.com What is health coaching? Health coaching is a voluntary program for members diagnosed with certain health conditions. We take a personalized and
MY CHOLESTEROL GUIDE. Take Action. Live Healthy! heart.org/cholesterol
MY CHOLESTEROL GUIDE Take Action. Live Healthy! heart.org/cholesterol UNDERSTANDING AND MANAGING CHOLESTEROL CONTENTS Understanding Risk...3 Why Am I at Risk?...3 How Will My Risk Factors Be Treated?...4
Cardiovascular disease (CVD) causes one-third of deaths in
SpeCial article 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult 2009 recommendations Jacques
nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
Repatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
Lecture 36 Dyslipidemia Therapeutics Barry LIPIDS:
LIPIDS: PATHOPHYSIOLOGY: TC or LDL-C = CVD HDL-C = CVD Association between TG and CVD not established o HyperTG associated with pancreatitis o Reducing TG w/ drug therapy doesn t CVD TYPES OF DYSLIPIDEMIA:
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
Lipid- Lowering Medica0ons. Drugs for Med Students Presented by Eric Campbell & Jen Chen
Lipid- Lowering Medica0ons Drugs for Med Students Presented by Eric Campbell & Jen Chen Rela0ve Effects of Lipid- Lowering Medica0ons Drug LDL HDL TG Sta0ns Fenofibrate Niacin Resins * Eze0mibe *Bile acid
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
1.* Dosage. A. Adults
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors [Developed, November 1994; Revised, October 1996; September 1997; September 1998; October 1999; November 1999; August 2000; September
Coronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
Lipid Goals: Update on their Status
Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2013 Lipid Goals: Update on their Status Katie Axford Eliza Dy Sarah
Managing Cholesterol
Managing Cholesterol Introduction Cholesterol is one of the most familiar medical words today. Cholesterol is a waxy substance that is very important for our body but could also be very dangerous if there
Lipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
Joshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
This policy addresses the use of Juxtapid (lomitapide) for the treatment of treatment of homozygous familial hypercholesterolemia.
Subject: Juxtapid (lomitapide) Original Effective Date: 10/30/2013 Policy Number: MCP-155 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Medical Policy is intended to
Medications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
7 KEYS. to Reduce Cholesterol. By Simeon Margolis, M.D., PH.D. & Roger S. Blumenthal, M.D. and the Editors of Johns Hopkins Health Alerts
7 KEYS to Reduce Cholesterol By Simeon Margolis, M.D., PH.D. & Roger S. Blumenthal, M.D. and the Editors of Johns Hopkins Health Alerts 7 KEYS 7 Keys to Reduce Cholesterol As many Americans are now aware,
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
Pharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
SESSION 5 2:15pm 3:45pm
SESSION 5 2:15pm 3:45pm Current Perspectives and Emerging Approaches in Lipid Management SPEAKERS Michael Miller, MD, FACC, FAHA Michael Blaha, MD, MPH Presenter Disclosure Information The following relationships
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
Repatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
New opportunities for targeting. multiple lipid pathways. Michel FARNIER, DIJON, FRANCE
New opportunities for targeting multiple lipid pathways Michel FARNIER, DIJN, FRANCE Lipid lowering drug therapy 60s and 70s - nicotinic acid -resins 70s to 90s - fibrates the 90s - statins Coronary heart
Low HDL and Diabetic Dyslipidemia
The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
Lipid Management Step Therapy Criteria with Medical Diagnoses Option*
Lipid Management Step Therapy Criteria with Medical Diagnoses Option* * Medical diagnoses are required for implementation of this option. Program may be implemented with the following options: Option One
Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Cardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK?
1 CARDIOVASCULAR DISEASE WHAT IS IT? WHAT IS THE ROLE OF CHOLESTEROL? HOW CAN WE REDUCE RISK? Perry J Weinstock, MD, F.A.C.C. Head, Division of Cardiovascular Disease Director of Clinical Cardiology Cooper
Your Guide to Managing and Understanding Your Cholesterol Levels
Your Guide to Managing and Understanding Your Cholesterol Levels Our goal at Bon Secours is to help you be well. Our experienced Heart Team includes cardiologists, cardiovascular surgeons, electrophysiologists,
Lipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
No relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity